Recent News

• 03.21.2025 - Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
• 03.21.2025 - Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
• 03.21.2025 - Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
• 03.07.2025 - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.07.2025 - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.07.2025 - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.05.2025 - Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
• 03.05.2025 - Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
• 03.05.2025 - Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

Recent Filings

• 03.21.2025 - SC 14D9 Solicitation, recommendation statements
• 03.21.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.21.2025 - EX-99.1 EX-99.1
• 03.21.2025 - SC TO-T Tender offer statement by Third Party
• 03.21.2025 - 8-K Current report
• 03.06.2025 - SC TO-C Written communication relating to an issuer or third party
• 03.05.2025 - SC14D9C Written communication relating to third party tender offer
• 03.05.2025 - SC TO-C Written communication relating to an issuer or third party
• 03.05.2025 - SC14D9C Written communication relating to third party tender offer
• 03.05.2025 - 8-K/A Current report